FDA says Qinprezo not ready for NDA; Sunesis slammed

Shares of Sunesis Pharmaceuticals plummeted nearly 67% in after-hours trading on 23 July after it revealed the FDA wants more data before the agency would consider reviewing an application for the company's experimental acute myeloid leukemia (AML) drug Qinprezo (vosaroxin).